Andarine

Andarine

Clinical data
ATC code	none
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name (2S)-3-(4-acetamido-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide
Synonyms	Acetamidoxolutamide; Androxolutamide; GTx-007; S-4
CAS Number	401900-40-1 N
PubChem CID	9824562
IUPHAR/BPS	7849
DrugBank	DB07423 Y
ChemSpider	8000309 Y
ChEMBL	CHEMBL125236 Y
ECHA InfoCard	100.230.653
Chemical and physical data
Formula	C19H18F3N3O6
Molar mass	441.357 g/mol
3D model (Jmol)	Interactive image
SMILES FC(F)(F)c1cc(ccc1[N+]([O-])=O)NC(=O)[C@@](O)(COc2ccc(cc2)NC(=O)C)C
InChI InChI=1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1 Y Key:YVXVTLGIDOACBJ-SFHVURJKSA-N Y
NY (what is this?)

Andarine (GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound.

Andarine is an orally active partial agonist for androgen receptors. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects. This suggests that it is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.